Therapeutic Interventions for Countering Leishmaniasis and Chagas's Disease: From Traditional Sources to Nanotechnological Systems

Pathogens
Eliana B SoutoSheefali Mahant

Abstract

The incidence of neglected diseases in tropical countries, such as Leishmaniasis and Chagas's disease, is attributed to a set of biological and ecological factors associated with the socioeconomic context of developing countries and with a significant burden to health care systems. Both Leishmaniasis and Chagas's disease are caused by different protozoa and develop diverse symptoms, which depend on the specific species infecting man. Currently available drugs to treat these disorders have limited therapeutic outcomes, frequently due to microorganisms' drug resistance. In recent years, significant efforts have been made towards the development of innovative drug delivery systems aiming to improve bioavailability and pharmacokinetic profiles of classical drug therapy. This paper discusses the key facts of Leishmaniasis and Chagas's disease, the currently available pharmacological therapies and the new drug delivery systems for conventional drugs.

References

Mar 1, 1986·The American Journal of Tropical Medicine and Hygiene·R E McCabeF G Araujo
Jun 1, 1987·Life Sciences·E YoshiharaT Nakae
Dec 1, 1986·Antimicrobial Agents and Chemotherapy·J D BermanG Lopez-Berestein
Jan 16, 1986·Biochimica Et Biophysica Acta·E Yoshihara, T Nakae
May 1, 1994·The Journal of Infection·D A Stevens
Jan 9, 1998·International Journal for Parasitology·R DurandM Deniau
May 15, 1998·The Journal of Pharmacy and Pharmacology·G Gonzalez-MartinA Osuna
Mar 8, 2000·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·G González-MartínA Osuna
Oct 26, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S SundarH W Murray
Jan 6, 2001·Memórias do Instituto Oswaldo Cruz·D G Colley
Feb 19, 2002·Molecular and Biochemical Parasitology·Phalgun B JoshiW Robert McMaster
Apr 12, 2002·Journal of Pharmaceutical Sciences·Begoña BrimePaloma Frutos
Jan 1, 2003·International Journal of Antimicrobial Agents·Julio A UrbinaAlvaro J Romanha
Mar 5, 2003·International Journal of Pharmaceutics·O KayserS L Croft
Jul 10, 2003·Kinetoplastid Biology and Disease·Alain Debrabant, Hira Nakhasi
Jul 17, 2003·Journal of Postgraduate Medicine·N C Hepburn
Dec 25, 2003·Antimicrobial Agents and Chemotherapy·Cynthia DemicheliFrédéric Frézard
Jun 19, 2004·Journal of Drug Targeting·Sanchaita LalaMukul Kumar Basu
Apr 12, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Maria Jose MorillaEder Lilia Romero
Jul 16, 2005·Memórias do Instituto Oswaldo Cruz·Maria Jose MorillaEder Lilia Romero
Apr 4, 2006·International Journal of Pharmaceutics·R H MüllerE B Souto
Aug 30, 2006·Human & Experimental Toxicology·José A CastroLaura C Bartel
Aug 31, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Caryn BernJorge Alvar
Mar 28, 2008·Proceedings of the National Academy of Sciences of the United States of America·Shane R WilkinsonIan Cheeseman
Aug 1, 2008·Journal of Cellular Biochemistry·V JimenezN Galanti
Sep 11, 2008·Current Clinical Pharmacology·Stefan PurscheGregor Dresemann
Nov 19, 2008·Fitoterapia·Bhuwan B MishraVinod K Tiwari
Jan 8, 2009·International Journal of Dermatology·Wendy F van der MeideRudy F M Lai A Fat
Jul 28, 2009·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Frédéric FrézardRaul R Ribeiro
Aug 22, 2009·Annals of Tropical Medicine and Parasitology·E A de AlmeidaR de J Pedro
Sep 24, 2009·Memórias do Instituto Oswaldo Cruz·Maria de Nazaré C SoeiroSolange Lisboa de Castro
Feb 27, 2010·The Lancet Infectious Diseases·Johan van GriensvenMarleen Boelaert
Mar 23, 2010·Journal of the American Academy of Dermatology·Panagiotis MitropoulosMindy Durkin-Konidas
May 12, 2010·Antimicrobial Agents and Chemotherapy·Denise da Gama Jaén BatistaMaria de Nazaré Correia Soeiro
Jul 8, 2010·Journal of Global Infectious Diseases·Shyam Sundar, Jaya Chakravarty

❮ Previous
Next ❯

Citations

Sep 17, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Carine S F MarquesPatricia Severino
Nov 5, 2019·Journal of Molecular Biology·Arpita SahaBibo Li
Nov 1, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Lutfun NaharSatyajit D Sarker
Jul 4, 2021·Biochimie·Simone S C OliveiraPatrícia Severino
Oct 10, 2021·Applied Microbiology and Biotechnology·Ana F S da CunhaSona Jain

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

International Journal of Medicinal Chemistry
Melanie Loedige
Journal of Biomedical Nanotechnology
Letícia de AlmeidaMárcia A S Graminha
Journal of the Royal Society of Medicine
R Lewinsohn
Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry
Blessing Atim Aderibigbe
© 2021 Meta ULC. All rights reserved